HTA Details
Update on Multiple Sclerosis and Chronic Cerebrospinal Venous Insufficiency (CCSVI)
- Publication date
-
2011-December-01
- Status
- Final
- Topic Area
- Immune System
- Recommendation
-
Ontario Health Technology Advisory Committee Recommendations:
- The Ontario Health Technology Advisory Committee has undertaken a preliminary evidence review of the safety and effectiveness of endovascular treatments for the proposed condition known as chronic cerebrospinal venous insufficiency in patients with multiple sclerosis and is unable to make any recommendation at this time due to the paucity of available evidence. The committee regards this treatment as experimental at this time.
- Evidence concerning the prevalence of chronic cerebrospinal venous insufficiency available up to July 2011 was reviewed by the Ontario Health Technology Advisory Committee, and no changes to the May 2010 recommendations were deemed necessary.
- Ministry Response
-
The Ministry of Health and Long-Term Care endorses this recommendation.
-
To read the full OHTAC Recommendation Report for this topic, contact our Health Innovation team using the contact form to request a digital copy.
Multiple sclerosis (MS) is a disease of the brain and spinal cord. The body’s immune system attacks the protective covering around the nerves that control movement and other body functions. This damage can result in slower or blocked communication between the brain and the rest of the body. People with MS may experience symptoms such as numbness, weakness, double vision or difficulty speaking. The disease tends to get worse over time and can lead to permanent disabilities.
A recent theory proposed that an abnormality in the vein that drains blood from the brain and spinal cord may be associated with MS and that treating this problem might hold promise as a treatment for MS. The abnormality is known as chronic cerebrospinal venous insufficiency.
Supporting Documents
Last Updated: February 24, 2026
